Novel therapeutics in multiple myeloma

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Most myeloma patients still experience recurrent relapse and eventually become resistant and/or intolerant of effective agents such as corticosteroids, alkylating agents, immune modulators (lenalidomide and thalidomide) or proteasome inhibitors such as bortezomib. Once this happens average survivals are less than one year. Progress has been made for such patients, however, with the demonstration of clinical benefit of novel proteasome inhibitors (carfilzomib) and immune modulators (pomalidomide). Pomalidomide when used with dexamethasone has activity in 30-60% of patients depending on disease stage. Carfilzomib is an irreversible proteasome inhibitor with favorable toxicity profile (minimal neuropathy) and response rates of 17-54% depending on the disease stage treated. Novel targets are also being explored. Histone deacetylase inhibitors such as vorinostat and panobinostat are in phase II testing although results from a randomized trial combining vorinostat with bortezomib were disappointing. Other small molecules or monoclonal antibodies with novel targets such as kinase inhibitors(AKT, CDK5) and cell surface receptors (e.g. elotuzumab) are undergoing active investigation.

Original languageEnglish (US)
JournalHematology
Volume17
Issue numberSUPPL. 1
DOIs
StatePublished - Apr 2012

Fingerprint

Proteasome Inhibitors
Multiple Myeloma
Histone Deacetylase Inhibitors
Thalidomide
Alkylating Agents
Cell Surface Receptors
Dexamethasone
Adrenal Cortex Hormones
Phosphotransferases
Therapeutics
Monoclonal Antibodies
Recurrence
Survival
Bortezomib
pomalidomide
carfilzomib
vorinostat

Keywords

  • Carfilzomib
  • Myeloma
  • Novel agents
  • Pomalidomide
  • Therapy
  • Vorinostat

ASJC Scopus subject areas

  • Hematology

Cite this

Novel therapeutics in multiple myeloma. / Stewart, Alexander Keith.

In: Hematology, Vol. 17, No. SUPPL. 1, 04.2012.

Research output: Contribution to journalArticle

@article{b29189a6090f4a18baf7c1483b01e5f5,
title = "Novel therapeutics in multiple myeloma",
abstract = "Most myeloma patients still experience recurrent relapse and eventually become resistant and/or intolerant of effective agents such as corticosteroids, alkylating agents, immune modulators (lenalidomide and thalidomide) or proteasome inhibitors such as bortezomib. Once this happens average survivals are less than one year. Progress has been made for such patients, however, with the demonstration of clinical benefit of novel proteasome inhibitors (carfilzomib) and immune modulators (pomalidomide). Pomalidomide when used with dexamethasone has activity in 30-60{\%} of patients depending on disease stage. Carfilzomib is an irreversible proteasome inhibitor with favorable toxicity profile (minimal neuropathy) and response rates of 17-54{\%} depending on the disease stage treated. Novel targets are also being explored. Histone deacetylase inhibitors such as vorinostat and panobinostat are in phase II testing although results from a randomized trial combining vorinostat with bortezomib were disappointing. Other small molecules or monoclonal antibodies with novel targets such as kinase inhibitors(AKT, CDK5) and cell surface receptors (e.g. elotuzumab) are undergoing active investigation.",
keywords = "Carfilzomib, Myeloma, Novel agents, Pomalidomide, Therapy, Vorinostat",
author = "Stewart, {Alexander Keith}",
year = "2012",
month = "4",
doi = "10.1179/102453312X13336169156131",
language = "English (US)",
volume = "17",
journal = "Hematology",
issn = "1024-5340",
publisher = "Taylor and Francis Ltd.",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Novel therapeutics in multiple myeloma

AU - Stewart, Alexander Keith

PY - 2012/4

Y1 - 2012/4

N2 - Most myeloma patients still experience recurrent relapse and eventually become resistant and/or intolerant of effective agents such as corticosteroids, alkylating agents, immune modulators (lenalidomide and thalidomide) or proteasome inhibitors such as bortezomib. Once this happens average survivals are less than one year. Progress has been made for such patients, however, with the demonstration of clinical benefit of novel proteasome inhibitors (carfilzomib) and immune modulators (pomalidomide). Pomalidomide when used with dexamethasone has activity in 30-60% of patients depending on disease stage. Carfilzomib is an irreversible proteasome inhibitor with favorable toxicity profile (minimal neuropathy) and response rates of 17-54% depending on the disease stage treated. Novel targets are also being explored. Histone deacetylase inhibitors such as vorinostat and panobinostat are in phase II testing although results from a randomized trial combining vorinostat with bortezomib were disappointing. Other small molecules or monoclonal antibodies with novel targets such as kinase inhibitors(AKT, CDK5) and cell surface receptors (e.g. elotuzumab) are undergoing active investigation.

AB - Most myeloma patients still experience recurrent relapse and eventually become resistant and/or intolerant of effective agents such as corticosteroids, alkylating agents, immune modulators (lenalidomide and thalidomide) or proteasome inhibitors such as bortezomib. Once this happens average survivals are less than one year. Progress has been made for such patients, however, with the demonstration of clinical benefit of novel proteasome inhibitors (carfilzomib) and immune modulators (pomalidomide). Pomalidomide when used with dexamethasone has activity in 30-60% of patients depending on disease stage. Carfilzomib is an irreversible proteasome inhibitor with favorable toxicity profile (minimal neuropathy) and response rates of 17-54% depending on the disease stage treated. Novel targets are also being explored. Histone deacetylase inhibitors such as vorinostat and panobinostat are in phase II testing although results from a randomized trial combining vorinostat with bortezomib were disappointing. Other small molecules or monoclonal antibodies with novel targets such as kinase inhibitors(AKT, CDK5) and cell surface receptors (e.g. elotuzumab) are undergoing active investigation.

KW - Carfilzomib

KW - Myeloma

KW - Novel agents

KW - Pomalidomide

KW - Therapy

KW - Vorinostat

UR - http://www.scopus.com/inward/record.url?scp=84859773382&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859773382&partnerID=8YFLogxK

U2 - 10.1179/102453312X13336169156131

DO - 10.1179/102453312X13336169156131

M3 - Article

C2 - 22507794

AN - SCOPUS:84859773382

VL - 17

JO - Hematology

JF - Hematology

SN - 1024-5340

IS - SUPPL. 1

ER -